Suet-Feung Chin, Author at Cancer Research UK Cambridge Institute

Associate Scientist

Research Group Home Page:: Caldas Group

Work address:: Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE

Publications:: Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses.

E-pub date: 31 Mar 2021; Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.

E-pub date: 28 Feb 2021; NRG1 fusions in breast cancer.

E-pub date: 31 Dec 2020; Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation.

E-pub date: 31 Dec 2020; The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences.

E-pub date: 30 Nov 2020; Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

E-pub date: 31 Oct 2020; Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

E-pub date: 31 Aug 2020; Sex differences in oncogenic mutational processes.

E-pub date: 31 Jul 2020; Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.

E-pub date: 31 May 2020; The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver.

E-pub date: 31 May 2020; A reference map of the human binary protein interactome.

E-pub date: 01 Apr 2020; Pan-cancer analysis of whole genomes.

E-pub date: 01 Feb 2020; Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer

E-pub date: 01 Feb 2020; Combination of BET and FGFR inhibition as a rational therapeutic strategy for invasive lobular breast cancer

E-pub date: 01 Feb 2020; Imaging breast cancer using hyperpolarized carbon-13 MRI.

E-pub date: 31 Dec 2019; A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

E-pub date: 31 Dec 2019; Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers

E-pub date: 01 Nov 2019; Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

E-pub date: 31 Jul 2019; BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

E-pub date: 31 Jul 2019; The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

E-pub date: 30 Apr 2019; Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

E-pub date: 30 Apr 2019; Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

E-pub date: 28 Feb 2019; PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer.

E-pub date: 28 Feb 2019; Dynamics of breast cancer relapse reveal molecularly defined late recurring ER-positive subgroups: Results from the METABRIC study

E-pub date: 01 Feb 2019; Multiplexed targeted digital sequencing of circulating tumor DNA to detect minimal residual disease in early and locally advanced breast cancer

E-pub date: 01 Feb 2019; Genome copy number entropy as predictor of response for neoadjuvant therapy in early breast cancer

E-pub date: 01 Feb 2019; Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

E-pub date: 31 Jan 2019; Genome-wide association study of germline variants and breast cancer-specific mortality.

E-pub date: 31 Jan 2019; Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

E-pub date: 31 Dec 2018; Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers

E-pub date: 30 Nov 2018; Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

E-pub date: 31 Jul 2018; Molecular Classification of Breast Cancer.

E-pub date: 01 Jul 2018; PO-387 Differential gene methylation in triple negative breast cancer and non-tumoral mammary tissue

E-pub date: 01 Jul 2018; PO-386 Decoding the regulatory role and epiclonal dynamics of DNA methylation in 1482 breast tumours

E-pub date: 01 Jul 2018; Bromodomain inhibitors for the treatment of invasive lobular carcinoma

E-pub date: 01 Jul 2018; Next Generation-Targeted Amplicon Sequencing (NG-TAS): An optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

E-pub date: 30 Jun 2018; Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers.

E-pub date: 01 Jun 2018; Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.

E-pub date: 31 May 2018; αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

E-pub date: 17 May 2018; Integrative cluster classification to predict pathological complete response to neoadjuvant chemotherapy in early breast cancer

E-pub date: 30 Apr 2018; Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14)

E-pub date: 30 Apr 2018; Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

E-pub date: 07 Mar 2018; Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts.

E-pub date: 05 Jan 2018; Body mass index and breast cancer survival: a Mendelian randomization analysis.

E-pub date: 01 Dec 2017; The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

E-pub date: 25 Aug 2017; Big data in cancer genomics

E-pub date: 31 Jul 2017; Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

E-pub date: 15 Jul 2017; Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers.

E-pub date: 18 Apr 2017; Subtype-specific micro-RNA expression signatures in breast cancer progression.

E-pub date: 01 Sep 2016; Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

E-pub date: 31 Aug 2016; A computational approach to discriminate between human and mouse reads in sequencing data from Patient Derived Tumour Xenografts

E-pub date: 01 Jul 2016; Identifying changes in mutational dynamics in patients with early breast cancer undergoing neoadjuvant chemotherapy

E-pub date: 01 Jul 2016; Dynamics of relapse in breast cancer

E-pub date: 01 Jul 2016; The somatic mutation profiles of 173 genes in over 2400 primary breast cancers

E-pub date: 01 Jul 2016; RATHER: High resolution molecular profiling of invasive lobular breast cancers

E-pub date: 01 Jul 2016; Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

E-pub date: 06 Jun 2016; The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

E-pub date: 10 May 2016; CDK7: A marker of poor prognosis and tractable therapeutic target in triple-negative breast cancer

E-pub date: 31 Jan 2016; Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

E-pub date: 05 Jan 2016; Molecular classification and testing of breast carcinoma

E-pub date: 31 Dec 2015; Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

E-pub date: 04 Nov 2015; BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

E-pub date: 31 Oct 2015; Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

E-pub date: 31 Aug 2015; Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

E-pub date: 01 Jun 2015; Identification of novel genetic markers of breast cancer survival.

E-pub date: 31 May 2015; Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

E-pub date: 23 Apr 2015; Common germline polymorphisms associated with breast cancer-specific survival.

E-pub date: 22 Apr 2015; Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.

E-pub date: 31 Mar 2015; A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

E-pub date: 31 Jan 2015; BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells.

E-pub date: 09 Jan 2015; Lymphocyte invasion of basal breast tumors is associated with wild-type p53

E-pub date: 31 Dec 2014; Identification of fusion genes through kinome-centered RNA sequencing in different types of solid tumors

E-pub date: 01 Nov 2014; Genome-driven integrated classification of breast cancer validated in over 7,500 samples.

E-pub date: 28 Aug 2014; Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

E-pub date: 01 Aug 2014; TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.

E-pub date: 01 Jul 2014; 22p * development of a brca1-like signature in triple negative breast cancers within the rather (rational therapy for breast cancer) consortium.

E-pub date: 31 May 2014; Processed pseudogenes acquired somatically during cancer development.

E-pub date: 09 Apr 2014; Defining clinically relevant molecular subtypes in lobular breast cancer within the RATHER consortium

E-pub date: 30 Nov 2013; A copy number and expression based classifier for breast cancer tumors

E-pub date: 01 Oct 2013; A targeted sequencing approach to characterize the mutational profiles of 178 genes in 2600 primary breast tumors

E-pub date: 01 Oct 2013; TOX3 mutations in breast cancer.

E-pub date: 31 Aug 2013; Master regulators of FGFR2 signalling and breast cancer risk.

E-pub date: 31 Aug 2013; A prognostic gene signature for metastasis-free survival of triple negative breast cancer patients.

E-pub date: 31 Aug 2013; The shaping and functional consequences of the microRNA landscape in breast cancer.

E-pub date: 16 May 2013; Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.

E-pub date: 02 May 2013; BRCA1-like signature in triple negative breast cancers within the RATHER (Rational Therapy for Breast Cancer) Consortium

E-pub date: 31 Mar 2013; Development of comprehensive molecular portraits of lobular breast cancer within the RATHER (Rational Therapy for Breast Cancer) Consortium.

E-pub date: 31 Mar 2013; Analysis of circulating tumor DNA to monitor metastatic breast cancer.

E-pub date: 28 Mar 2013; Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.

E-pub date: 21 Feb 2013; Ab-initio calculation of C and CO adsorption on the Co (110) surface

E-pub date: 31 Jan 2013; Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes.

E-pub date: 22 Dec 2012; Copy number variation and risk of chemotherapy-related infection

E-pub date: 30 Nov 2012; Copynumber: Efficient algorithms for single- and multi-track copy number segmentation.

E-pub date: 04 Nov 2012; Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling (Science Translational Medicine (2012) 4, (161er6))

E-pub date: 31 Oct 2012; Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer.

E-pub date: 31 Oct 2012; Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling.

E-pub date: 24 Oct 2012; Calling sample mix-ups in cancer population studies.

E-pub date: 31 Aug 2012; Non-invasive Monitoring of Metastatic Breast Cancer by Circulating Tumour DNA – a Comparison With Circulating Tumour Cells

E-pub date: 01 Jul 2012; Experimental and theoretical study of electron-beam-induced spin-reorientation transition reversal in the CO/Co(110) system

E-pub date: 30 Jun 2012; The landscape of cancer genes and mutational processes in breast cancer.

E-pub date: 16 May 2012; The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

E-pub date: 18 Apr 2012; Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.

E-pub date: 18 Apr 2012; The clonal and mutational evolution spectrum of primary triple-negative breast cancers.

E-pub date: 04 Apr 2012; MNK2 inhibits eIF4G activation through a pathway involving serine-arginine-rich protein kinase in skeletal muscle.

E-pub date: 14 Feb 2012; Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

E-pub date: 04 Jan 2012; Modification of the secondary-electron spin polarization in Co/Cu(110) films via gaseous adsorbates

E-pub date: 31 Oct 2011; Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma.

E-pub date: 31 Oct 2011; Electron Beam Tuning of the Magnetic Anisotropy in Co/Cu(110) Films

E-pub date: 01 Jun 2011; NOVEL PROGNOSTIC TARGETS IDENTIFIED USING INTEGRATED ANALYSIS OF COPY NUMBER AND EXPRESSION DATA IN OESOPHAGEAL ADENOCARCINOMA

E-pub date: 01 Apr 2011; Novel prognostic targets identified using integrated analysis of copy number and expression data in esophageal adenocarcinoma

E-pub date: 31 Mar 2011; ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.

E-pub date: 31 Mar 2011; Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

E-pub date: 30 Jun 2010; Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas.

E-pub date: 31 May 2010; Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer.

E-pub date: 01 Mar 2010; The pitfalls of platform comparison: DNA copy number array technologies assessed.

E-pub date: 08 Dec 2009; A metadata approach for clinical data management in translational genomics studies in breast cancer.

E-pub date: 30 Nov 2009; The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene.

E-pub date: 19 Nov 2009; Germline CDH1 deletions in hereditary diffuse gastric cancer families.

E-pub date: 01 May 2009; Chromosome translocations and fusion genes in breast cancer.

E-pub date: 31 Dec 2008; High-resolution array CGH clarifies events occurring on 8p in carcinogenesis.

E-pub date: 07 Oct 2008; PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes.

E-pub date: 31 Aug 2008; Chromosome translocations in breast cancer

E-pub date: 01 Aug 2008; NRG1 is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene

E-pub date: 01 Aug 2008; ESR1 gene amplification in breast cancer: a common phenomenon?

E-pub date: 31 Jul 2008; Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.

E-pub date: 06 May 2008; High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.

E-pub date: 01 May 2008; Regulation of p53 tetramerization and nuclear export by ARC.

E-pub date: 26 Dec 2007; MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.

E-pub date: 31 Aug 2007; High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

E-pub date: 31 Aug 2007; Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event.

E-pub date: 31 May 2007; Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.

E-pub date: 22 Mar 2007; Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors.

E-pub date: 01 Mar 2007; p300 is required for orderly G1/S transition in human cancer cells.

E-pub date: 31 Dec 2006; ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.

E-pub date: 31 Oct 2006; Spatial associations of humus, nutrients and soils in mixed dipterocarp forest at Lambir, Sarawak, Malaysian Borneo

E-pub date: 01 Sep 2006; Comparative genomic hybridization of esophageal adenocarcinoma and squamous cell carcinoma cell lines.

E-pub date: 01 Aug 2006; Impaired transforming growth factor beta signalling in Barrett’s carcinogenesis due to frequent SMAD4 inactivation.

E-pub date: 01 Jun 2006; Erratum: Comparative genomic hybridization of esophageal adenocarinoma and squamous cell carcinoma cell lines (Diseases of the Esophagus (2006) vol. 19 (10-34))

E-pub date: 31 Mar 2006; Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT.

E-pub date: 31 Mar 2006; Human and mouse oligonucleotide-based array CGH.

E-pub date: 30 Nov 2005; A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes.

E-pub date: 31 Jul 2005; Shadow-evaporated nanometre-sized gaps and their use in electrical studies of nanocrystals

E-pub date: 01 Jun 2005; Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

E-pub date: 01 May 2005; Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays.

E-pub date: 01 Feb 2005; Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression.

E-pub date: 01 Oct 2004; A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene.

E-pub date: 30 Sep 2004; p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels.

E-pub date: 30 Apr 2004; EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

E-pub date: 31 Oct 2003; A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples.

E-pub date: 01 Oct 2003; DNA damage-induced [Zn(2+)](i) transients: correlation with cell cycle arrest and apoptosis in lymphoma cells.

E-pub date: 31 Aug 2002; Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers : a new approach for the molecular analysis of paraffin-embedded cancer tissue.

E-pub date: 01 May 2001; Absence of rearrangements in the BRCA2 gene in human cancers.

E-pub date: 01 Jan 2001; Molecular cytogenetic analysis of breast cancer cell lines.

E-pub date: 01 Nov 2000; Mutations truncating the EP300 acetylase in human cancers.

E-pub date: 01 Mar 2000; MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines.

E-pub date: 30 Nov 1999; Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells.

E-pub date: 01 Sep 1999; On the spheroidal bag

E-pub date: 30 Sep 1983; Show all Hide all

Suet-Feung Chin

Associate Scientist

Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses.

Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.

NRG1 fusions in breast cancer.

Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation.

The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences.

Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

Sex differences in oncogenic mutational processes.

Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver.

A reference map of the human binary protein interactome.

Pan-cancer analysis of whole genomes.

Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer

Combination of BET and FGFR inhibition as a rational therapeutic strategy for invasive lobular breast cancer

Imaging breast cancer using hyperpolarized carbon-13 MRI.

A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.

Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers

Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.

BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer.

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

PDLIM2 is a marker of adhesion and β-catenin activity in triple-negative breast cancer.

Dynamics of breast cancer relapse reveal molecularly defined late recurring ER-positive subgroups: Results from the METABRIC study

Multiplexed targeted digital sequencing of circulating tumor DNA to detect minimal residual disease in early and locally advanced breast cancer

Genome copy number entropy as predictor of response for neoadjuvant therapy in early breast cancer

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Genome-wide association study of germline variants and breast cancer-specific mortality.

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers

Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.

Molecular Classification of Breast Cancer.

PO-387 Differential gene methylation in triple negative breast cancer and non-tumoral mammary tissue

PO-386 Decoding the regulatory role and epiclonal dynamics of DNA methylation in 1482 breast tumours

Bromodomain inhibitors for the treatment of invasive lobular carcinoma

Next Generation-Targeted Amplicon Sequencing (NG-TAS): An optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers.

Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.

αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.

Integrative cluster classification to predict pathological complete response to neoadjuvant chemotherapy in early breast cancer

Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14)

Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.

Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts.

Body mass index and breast cancer survival: a Mendelian randomization analysis.

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Big data in cancer genomics

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers.

Subtype-specific micro-RNA expression signatures in breast cancer progression.

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

A computational approach to discriminate between human and mouse reads in sequencing data from Patient Derived Tumour Xenografts

Identifying changes in mutational dynamics in patients with early breast cancer undergoing neoadjuvant chemotherapy

Dynamics of relapse in breast cancer

The somatic mutation profiles of 173 genes in over 2400 primary breast cancers

RATHER: High resolution molecular profiling of invasive lobular breast cancers

Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

CDK7: A marker of poor prognosis and tractable therapeutic target in triple-negative breast cancer

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Molecular classification and testing of breast carcinoma

Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Identification of novel genetic markers of breast cancer survival.

Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.

Common germline polymorphisms associated with breast cancer-specific survival.

Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53.

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells.

Lymphocyte invasion of basal breast tumors is associated with wild-type p53

Identification of fusion genes through kinome-centered RNA sequencing in different types of solid tumors

Genome-driven integrated classification of breast cancer validated in over 7,500 samples.

Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.

22p * development of a brca1-like signature in triple negative breast cancers within the rather (rational therapy for breast cancer) consortium.

Processed pseudogenes acquired somatically during cancer development.

Defining clinically relevant molecular subtypes in lobular breast cancer within the RATHER consortium